Titan Pharmaceuticals has presented data which it says furtherdemonstrate improvement in motor function and quality of life for patients treated with its potential Parkinson's disease treatment spheramine.
The interim Phase I/II study results, presented at the International Congress on Parkinson's Disease in Finland, indicate that all six patients in the study experienced substantial clinical improvement, and also suggest a sustained effect after a single treatment, with patients on study ranging from seven-15 months post-treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze